Skip to main content
. 2022 Jan 13;14:9. doi: 10.1186/s13195-021-00955-9

Fig. 2.

Fig. 2

Plasma LCN2 in AD and MCI cases of cohorts 1 and 2. A Plasma LCN2 concentrations in HC, MCI-AD, and AD of cohort 1. B Plasma LCN2 concentrations in HC, amnestic MCI, and AD of cohort 2. C Areas under the curve (AUC) from receiver operating characteristic with 95% confidence intervals (95% CI) and p-values from assessment of diagnostic accuracy in cohort 1 and 2. D Plasma LCN2 concentrations in HC, MCI-VCI, and VaD of cohort 1. Comparison of biomarker concentrations of diagnostic groups was performed with linear regression models; age and sex were included as covariates. Multiple comparisons were performed with Tukey contrasts. P-values are indicated above dot columns when significant. Bars (A, B, D) indicate mean and standard error of mean. HC, healthy controls; MCI (AD), mild cognitive impairment with positive biomarkers for AD-related pathology; AD, Alzheimer’s disease; MCI (amnestic), mild cognitive impairment with disturbance of memory function; MCI-VCI, mild vascular cognitive impairment; VaD, vascular dementia or major vascular cognitive impairment